

11 May 2020

ASX ANNOUNCEMENT

SECOND PATIENT SUCCESSFULLY IMPLANTED IN SAVR TRIAL

Admedus Limited (ASX:AHZ) (**Admedus** or the **Company**) announces the successful implantation of an ADAPT[®] treated DurAVR[™] 3D single-piece aortic valve in a second patient at the University Hospitals Leuven, Belgium, in its first-in-human surgical aortic valve replacement (SAVR) study.

“The first patient, implanted with DurAVR[™] 3D single-piece aortic valve on 26 March 2020 is doing well, over a month post implantation and patient two is recovering as expected. Given the challenges that the COVID-19 pandemic is presenting for hospitals, it is encouraging to see the second surgery completed. We are grateful to the surgeon and the patient for undergoing the procedure,” Admedus Chief Executive Officer, Mr Wayne Paterson, said.

Fifteen patients are to be enrolled in this study, and followed up for six months after implantation.

Admedus will provide a further update on the trial once enrolment is complete.

More information on the clinical trial is available here:
<https://clinicaltrials.gov/ct2/show/NCT04178213>

ENDS

About Admedus Limited (ASX: AHZ)

Admedus Ltd is a structural heart company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Its focus is on developing next generation technologies with world class partners.


Admedus Limited

Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland 4066

Customer Service:

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299
E: info@admedus.com W: admedus.com



Authorisation and Additional information

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

For more information:

Ms Kyahn Williamson
WE Communications
E: WE-AUAdmedus@we-worldwide.com
P: +61 401 018 828

www.admedus.com

Twitter: @Admedus

Facebook: www.facebook.com/admedus/